AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Impact BioMedical Receives Patent for Infectious Disease Control Method
ByAinvest
Monday, Aug 18, 2025 9:38 am ET1min read
Impact BioMedical received a US patent for a method to control infectious diseases. The company, a subsidiary of DSS, Inc., focuses on drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases. Its subsidiary, Global BioLife, is researching a universal therapeutic drug platform, a sugar substitute called Laetose, a mosquito repellent fragrance, and an antimicrobial medication called Equivir/Nemovir.
Impact BioMedical Inc. (IBO), a subsidiary of DSS, Inc., has announced the issuance of a U.S. patent for its 3F™ technology platform, which focuses on controlling infectious diseases through plant-based functional fragrances. The patent, valid until December 2038, covers unique compositions with antimicrobial and antiviral properties effective against various pathogens, including E. coli, MRSA, influenza, rhinovirus, and M. tuberculosis [1].The 3F™ technology addresses the growing infectious disease market, projected to expand from $21.7B in 2024 to $34B in 2023, with a CAGR of 5.77% [1]. The company is actively pursuing partnerships to commercialize 3F™ technology in the US and globally.
IBO is a biotechnology company specializing in discovering, developing, and patenting innovative healthcare solutions. Its subsidiary, Global BioLife, is researching a universal therapeutic drug platform, a sugar substitute called Laetose, a mosquito repellent fragrance, and an antimicrobial medication called Equivir/Nemovir. The company's strategic partnerships and acquisitions, such as the recent merger with Dr. Ashleys Limited and the acquisition of Celios®, aim to accelerate market development and generate immediate revenue [2, 3].
The successful issuance of this patent demonstrates IBO's commitment to addressing unmet healthcare needs and its ability to deliver unique proprietary technology. As the company continues to grow, investors can expect to see further advancements in its drug discovery and prevention, inhibition, and treatment of neurological, oncological, and immune-related diseases.
References:
[1] https://www.stocktitan.net/news/IBO/
[2] https://www.stocktitan.net/news/IBO/
[3] https://www.stocktitan.net/news/IBO/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet